Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma

CONCLUSION: Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.PMID:38485811 | PMC:PMC10903519 | DOI:10.1007/s44313-024-00004-y

Source: Blood Research - March 15, 2024 Category: Hematology Authors: Bitna Jang Jonghyun Jeong Kyu-Nam Heo Youngil Koh Ju-Yeun Lee Source Type: research